BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8720314)

  • 1. Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Arzneimittelforschung; 1996 Feb; 46(2):201-4. PubMed ID: 8720314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
    Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
    Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Jpn J Pharmacol; 1996 Jan; 70(1):65-72. PubMed ID: 8822090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
    Akiyama T; Shimizu M; Okabe M; Tamaoki T; Akinaga S
    Anticancer Drugs; 1999 Jan; 10(1):67-78. PubMed ID: 10194549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines.
    Shimizu E; Zhao MR; Nakanishi H; Yamamoto A; Yoshida S; Takada M; Ogura T; Sone S
    Oncology; 1996; 53(6):494-504. PubMed ID: 8960146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.
    Courage C; Snowden R; Gescher A
    Br J Cancer; 1996 Oct; 74(8):1199-205. PubMed ID: 8883405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines.
    Sedlak J; Hunakova L; Duraj J; Chorvath B; Novotny L
    Anticancer Drugs; 1995 Feb; 6(1):70-6. PubMed ID: 7756686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.
    Begemann M; Kashimawo SA; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Anticancer Res; 1998; 18(4A):2275-82. PubMed ID: 9703866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
    Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.
    Alkan SS; Rutschmann S; Grogg D; Erb P
    Cell Immunol; 1993 Aug; 150(1):137-48. PubMed ID: 8102085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
    Andrejauskas-Buchdunger E; Regenass U
    Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
    Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
    Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
    Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
    Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
    Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
    Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
    Luo W; Sharif TR; Houghton PJ; Sharif M
    Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors.
    Siegrist W; Sauter P; Eberle AN
    J Recept Signal Transduct Res; 1995; 15(1-4):283-96. PubMed ID: 8903945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
    Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
    Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.